LAUSANNE, Switzerland & BOSTON--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, is proud to announce the extension of funding from the Combating ...

Frost, Kelly M., et al. "Rolling the evolutionary dice: Neisseria commensals as proxies for elucidating the underpinnings of antibiotic resistance mechanisms and evolution in human pathogens." ...

In recent years, the World Health Organization (WHO) has repeatedly warned of the increase in microbes resistant to antibiotics. Especially multi-resistant bacteria threaten the global healthcare ...

In a recent study published in Nature Communications, researchers performed cellular, biochemical, and structural analyses to assess the multiple transferable resistance repressor (MtrR) binding and ...

This image shows several dozen Neisseria gonorrhoeae bacteria – the cause of a painful and life-threatening disease called gonorrhea. Gonorrhea is a sexually transmitted disease, but it can also be ...

OraSure TechnologiesOSUR recently announced that it submitted two applications to the FDA seeking approval for its two new at-home tests for sexually transmitted infections (STIs), aiming to expand ...

An important Phase 3 trial has shown that a new drug that targets gonorrhea works as well as the last existing antibiotic to treat the sexually transmitted infection, results that could lead to ...

The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced ...

“We are pleased to provide continued support for the preclinical development of Debio 1453,” said Erin Duffy, PhD, R&D Chief of CARB-X. “Neisseria gonorrhoeae has become resistant to every antibiotic ...